The University of Chicago Header Logo

Connection

Ernst Lengyel to Cell Line, Tumor

This is a "connection" page, showing publications Ernst Lengyel has written about Cell Line, Tumor.
Connection Strength

1.987
  1. Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. Mol Cancer Ther. 2025 Aug 01; 24(8):1252-1264.
    View in: PubMed
    Score: 0.150
  2. NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity. Nature. 2025 Sep; 645(8082):1051-1059.
    View in: PubMed
    Score: 0.150
  3. Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression. Cancer Cell. 2025 Aug 11; 43(8):1495-1511.e7.
    View in: PubMed
    Score: 0.149
  4. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance. Cancer Res. 2020 04 15; 80(8):1748-1761.
    View in: PubMed
    Score: 0.103
  5. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 10; 15(10):2282-2293.
    View in: PubMed
    Score: 0.080
  6. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10.
    View in: PubMed
    Score: 0.071
  7. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28.
    View in: PubMed
    Score: 0.070
  8. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther. 2013 Dec; 12(12):2628-39.
    View in: PubMed
    Score: 0.066
  9. Epithelial ovarian cancer experimental models. Oncogene. 2014 Jul 10; 33(28):3619-33.
    View in: PubMed
    Score: 0.065
  10. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012 Dec; 2(12):1100-8.
    View in: PubMed
    Score: 0.062
  11. The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol. 2012 Jan; 124(1):134-41.
    View in: PubMed
    Score: 0.058
  12. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51.
    View in: PubMed
    Score: 0.056
  13. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71.
    View in: PubMed
    Score: 0.054
  14. Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31; 30(13):1566-76.
    View in: PubMed
    Score: 0.054
  15. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010 Jan; 12(1):1-10.
    View in: PubMed
    Score: 0.051
  16. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem. 2008 Feb 01; 283(5):2822-34.
    View in: PubMed
    Score: 0.044
  17. Selective Alanine Transporter Utilization Is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Res. 2025 Sep 15; 85(18):3471-3489.
    View in: PubMed
    Score: 0.038
  18. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 Jul; 643(8072):810-819.
    View in: PubMed
    Score: 0.037
  19. Tumor microenvironment-induced FOXM1 regulates ovarian cancer stemness. Cell Death Dis. 2024 05 28; 15(5):370.
    View in: PubMed
    Score: 0.035
  20. Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. JCI Insight. 2023 03 22; 8(6).
    View in: PubMed
    Score: 0.032
  21. Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell. 2021 06 10; 184(12):3163-3177.e21.
    View in: PubMed
    Score: 0.028
  22. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386.
    View in: PubMed
    Score: 0.025
  23. Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. Proc Natl Acad Sci U S A. 2019 10 22; 116(43):21493-21500.
    View in: PubMed
    Score: 0.025
  24. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728.
    View in: PubMed
    Score: 0.024
  25. Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Sci Rep. 2019 03 26; 9(1):5195.
    View in: PubMed
    Score: 0.024
  26. Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecol Oncol. 2019 05; 153(2):405-415.
    View in: PubMed
    Score: 0.024
  27. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 01 07; 216(1):176-194.
    View in: PubMed
    Score: 0.024
  28. A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials. 2019 01; 190-191:63-75.
    View in: PubMed
    Score: 0.023
  29. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9.
    View in: PubMed
    Score: 0.023
  30. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018 09; 20(9):1074-1083.
    View in: PubMed
    Score: 0.023
  31. An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nat Commun. 2017 11 24; 8(1):1775.
    View in: PubMed
    Score: 0.022
  32. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266.
    View in: PubMed
    Score: 0.021
  33. Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 04 01; 77(7):1684-1696.
    View in: PubMed
    Score: 0.021
  34. A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 06; 22(5):494-506.
    View in: PubMed
    Score: 0.021
  35. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739.
    View in: PubMed
    Score: 0.020
  36. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res. 2017 01; 15(1):78-92.
    View in: PubMed
    Score: 0.020
  37. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016 08 26; 7:12645.
    View in: PubMed
    Score: 0.020
  38. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60.
    View in: PubMed
    Score: 0.019
  39. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62.
    View in: PubMed
    Score: 0.019
  40. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015 May 10; 6(13):11342-56.
    View in: PubMed
    Score: 0.018
  41. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014 Jan; 184(1):271-81.
    View in: PubMed
    Score: 0.017
  42. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression. Am J Pathol. 2013 May; 182(5):1876-89.
    View in: PubMed
    Score: 0.016
  43. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012 Apr 15; 130(8):1787-97.
    View in: PubMed
    Score: 0.014
  44. CD95 promotes tumour growth. Nature. 2010 May 27; 465(7297):492-6.
    View in: PubMed
    Score: 0.013
  45. Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Hum Mol Genet. 2009 Oct 01; 18(19):3632-44.
    View in: PubMed
    Score: 0.012
  46. Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. Endocrinology. 2009 Sep; 150(9):4306-15.
    View in: PubMed
    Score: 0.012
  47. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008 Apr 01; 22(7):894-907.
    View in: PubMed
    Score: 0.011
  48. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007 Nov 01; 6(21):2585-90.
    View in: PubMed
    Score: 0.011
  49. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11400-5.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.